JonesResearch analyst Debanjana Chatterjee raised the firm’s price target on Pharvaris (PHVS) to $52 from $48 and keeps a Buy rating on the shares, citing an increased peak sales projection for deucrictibant IR.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
- 3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
- Texas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls
- Pharvaris initiated with an Outperform at Wolfe Research
- Pharvaris price target raised to $42 from $41 at Wedbush